Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 1, 2022JAMA

Diagnosis and Management of Multiple Myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAndrew J. CowanCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South AfricaDGDamian J. GreenUniversity of MiamiMKMary KwokUniversity of Washington

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cowan et al. (2022) studied this question.

synapsesocial.com/papers/69d75888086f9d6299f308c8https://doi.org/10.1001/jama.2022.0003
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Association of response endpoints with survival outcomes in multiple myeloma2013 · 163 citations
  2. 2Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma2008 · 346 citations
  3. 3Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial2020 · 703 citations